Received Feb 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
Menveo one vial presentation administered to patients under 10 year of age; This non-serious case was reported by a physician via sales rep and described the occurrence of inappropriate age at vaccine administration in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. On an unknown date, the patient received Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: Menveo one vial presentation administered to patients under 10 year of age). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK Receipt Date: 10-FEB-2025 The doctor stated that several patients under 10 year old received Menveo one vial presentation which led to inappropriate age at vaccine administration. The doctor wanted to know if these children under 10 year old who had been administered with Menveo one vial presentation will be protected from MCV4 compared with Menveo 2 vials presentation. The vaccine administration facility is the same as primary reporter. Consented to follow up.